Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

AMPAC Fine Chemicals Acquires Manufacturing Complex In Petersburg, Virginia

10/03/2016
AMPAC Fine Chemicals acquired the assets of UniTao Pharmaceuticals, comprising of the former Boehringer Ingelheim manufacturing facility in Petersburg, Virginia.

According to AMPAC officials, the Petersburg facility, now known as AFC-Virginia, includes four plants with multiple cGMP manufacturing lines totaling more than 80,000 gallons of cGMP capacity, the most recent of which was brought on-line in 2009. AFC-VA has a long history of producing Schedule II Controlled Substances. Capabilities also include High Potency manufacturing suites plus multiple 100 to 2000 gallon production bays.

Dr. Aslam Malik, AFC's President/CEO, said, "This is a world-class active pharmaceutical ingredient manufacturing facility with a long history of producing Controlled Substances and Highly Potent APIs. It is a perfect fit for AFC's growing demand for APIs."

"We have also retained a core team of experienced professionals at the Petersburg facility to support cGMP production of intermediates and APIs,” Dr. Malik added. “This will ensure a seamless integration into AFC's network of production plants. AFC is witnessing robust customer demand for our core technologies combined with our development & manufacturing expertise. Customer response to this acquisition has been positive since it provides additional cGMP capacity in the US to support their current and future API needs."

This transaction is a continuation of AFC's targeted acquisition strategy, first demonstrated in its successful integration of the AFC-Texas plant, which is now supporting numerous validated programs. Additionally, the AFC-California facility is undergoing a major expansion that is scheduled for completion in early 2017.

AFC is a U.S.-based company with demonstrated capabilities in process development, scale-up, and cGMP-compliant commercial production of active pharmaceutical ingredients and registered intermediates for pharmaceutical and biotechnology customers. Its specially engineered facilities and experienced staff allow AFC to safely produce highly energetic compounds at commercial scale.

Exclusive Research